Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Accelerate@Babraham supports early-stage life sciences ventures within the Babraham Research Campus’ community
CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
People aged 65 to 69 and the clinically vulnerable will be offered the jab from today
The entry deadline for the 2021 International Clinical Researcher of the Year has been extended to the 16th of April.
Scheme will run for 12 months in the Leicester, Leicestershire and Rutland areas
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
In the RECOVERY trial, tocilizumab treatment significantly reduced deaths caused by COVID-19
German CDMO will build new manufacturing capabilities at CGT Catapult site
Future reforms will aim to bring health and care services closer together
Participants lost on average 14.9% of their baseline body weight
WHO’s SAGE panel backs wide use of jab in adults, including in people aged over 65
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)